StockNews.com downgraded shares of SCYNEXIS (NASDAQ:SCYX – Free Report) from a hold rating to a sell rating in a report published on Thursday.
SCYNEXIS Stock Up 8.6 %
NASDAQ SCYX opened at $0.93 on Thursday. SCYNEXIS has a 52 week low of $0.82 and a 52 week high of $3.07. The stock has a market capitalization of $35.37 million, a PE ratio of -1.26 and a beta of 1.67. The firm has a 50 day moving average of $1.08 and a two-hundred day moving average of $1.25.
SCYNEXIS (NASDAQ:SCYX – Get Free Report) last posted its quarterly earnings results on Wednesday, March 12th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.13. SCYNEXIS had a negative net margin of 425.41% and a negative return on equity of 66.21%. The company had revenue of $0.98 million during the quarter.
Institutional Inflows and Outflows
About SCYNEXIS
SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.
Read More
- Five stocks we like better than SCYNEXIS
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.